| | | | Focusing on RET in cancer: | | | | | | RET alterations are primary oncogenic drivers1 | | | |
| | | | | Normally, RET kinase signaling is tightly controlled through a ligand-dependent mechanism which regulates cell migration, growth, and survival.1,2 In certain cancers, aberrant RET gene alterations can lead to expression of an abnormal RET kinase that is constitutively active and promotes uncontrolled tumor cell proliferation.1 | | | | | | | Learn more |  |
| |
| | | | | | |  | | | | | | Mutual exclusivity | | | | RET alterations are often mutually exclusive of other oncogenic driver alterations, such as EGFR, ALK, NTRK, and BRAF.1,3 | | | |
| | | | | Oncogenic RET alterations can be either gene fusions or activating point mutations2 | | | | | |  | | | | | | RET fusions | | | | (eg, KIF5B-RET, CCDC6-RET)2 | | | | | |  | | | | | | Activating RET point mutations | | | | (eg, C634R, M918T)2 | | | | | | Only a molecular test can identify if a RET alteration is present in a patient’s tumor sample.4 Collaboration with your pathology lab partners can help determine whether a tissue-efficient NGS method or a single-gene test, like FISH, is appropriate for your patients. | | | |
| | | Learn about RET-altered
cancer types | | |
| |
| | | | | | | ALK=anaplastic lymphoma kinase; BRAF=v‑raf murine sarcoma viral oncogene homolog B; EGFR=epidermal growth factor receptor; FISH=fluorescence in situ hybridization; HER2=human epidermal growth factor receptor 2; MET=MET proto‑oncogene; NGS=next-generation sequencing; NTRK=neurotrophic tropomyosin receptor kinase; PD‑L1=programmed death‑ligand 1; RET=rearranged during transfection; ROS1=c‑ros oncogene 1. | | | | | | References: 1. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET‑driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):150. 2. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Cancer Rev. 2014;14(3):173‑186. 3. Agrawal N, Akbani R, Aksoy BA, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):679‑690. 4. Nagahashi M, Shimada Y, Ichikawa H, et al. Next generation sequencing‑based gene panel tests for the management of solid tumors. Cancer Sci. 2019;110(1):6‑15. | | | | | | Copyright © 2019 Loxo Oncology, Inc, 2019, All Rights Reserved. LMA-US-RET-092019-00004 | | | | | |  | | | |
|
|
|